Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tigger transposable element-derived protein 5 (TIGD5) is a nuclear DNA-binding protein encoded by the TIGD5 gene situated at chromosome 8q24.3. It belongs to the tigger subfamily of the pogo superfamily, evolutionary descendants of DNA-mediated transposons originally found in fungi, nematodes, and closely related to other eukaryotic transposases. TIGD5 is structurally similar to major mammalian centromere proteins (such as centromere protein B). Its molecular function is annotated as nucleic acid binding, although the precise biological role remains obscure. Recent data suggest TIGD5 has a context-specific biological function in ovarian cancer, where it is frequently co-amplified with the MYC oncogene; paradoxically, higher TIGD5 expression correlates with poor prognosis but appears to suppress growth, adhesion, and invasion in model cell lines, supporting a putative tumor suppressor function. No drugs, directed therapies, or pharmacological modulators target TIGD5, nor does it have recognized involvement in other diseases or cellular signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tigger transposable element-derived protein 5 (TIGD5).